Literature DB >> 21270842

Atrial fibrillation in 2010: advances in treatment and management.

Stuart J Connolly1.   

Abstract

Clinical research into the management of atrial fibrillation—the most common serious arrhythmia—has mostly focused on arrhythmia prevention and the reduction of vascular events and death. In 2010, important advances have been made in stroke prevention with new anticoagulants and in atrial fibrillation rhythm management.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21270842     DOI： 10.1038/nrcardio.2010.206

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  7 in total

1.  Lenient versus strict rate control in patients with atrial fibrillation.

Authors:  Isabelle C Van Gelder; Hessel F Groenveld; Harry J G M Crijns; Ype S Tuininga; Jan G P Tijssen; A Marco Alings; Hans L Hillege; Johanna A Bergsma-Kadijk; Jan H Cornel; Otto Kamp; Raymond Tukkie; Hans A Bosker; Dirk J Van Veldhuisen; Maarten P Van den Berg
Journal:  N Engl J Med       Date:  2010-03-15       Impact factor: 91.245

2.  Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.

Authors:  John W Eikelboom; Martin O'Donnell; Salim Yusuf; Rafael Diaz; Greg Flaker; Robert Hart; Stefan Hohnloser; Campbell Joyner; Jack Lawrence; Prem Pais; Janice Pogue; David Synhorst; Stuart J Connolly
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

3.  Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.

Authors:  Renato D Lopes; John H Alexander; Sana M Al-Khatib; Jack Ansell; Raphael Diaz; J Donald Easton; Bernard J Gersh; Christopher B Granger; Michael Hanna; John Horowitz; Elaine M Hylek; John J V McMurray; Freek W A Verheugt; Lars Wallentin
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

4.  Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.

Authors: 
Journal:  Am Heart J       Date:  2010-03       Impact factor: 4.749

5.  Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.

Authors:  Lars Wallentin; Salim Yusuf; Michael D Ezekowitz; Marco Alings; Marcus Flather; Maria Grazia Franzosi; Prem Pais; Antonio Dans; John Eikelboom; Jonas Oldgren; Janice Pogue; Paul A Reilly; Sean Yang; Stuart J Connolly
Journal:  Lancet       Date:  2010-09-18       Impact factor: 79.321

6.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).

Authors:  A John Camm; Paulus Kirchhof; Gregory Y H Lip; Ulrich Schotten; Irene Savelieva; Sabine Ernst; Isabelle C Van Gelder; Nawwar Al-Attar; Gerhard Hindricks; Bernard Prendergast; Hein Heidbuchel; Ottavio Alfieri; Annalisa Angelini; Dan Atar; Paolo Colonna; Raffaele De Caterina; Johan De Sutter; Andreas Goette; Bulent Gorenek; Magnus Heldal; Stefan H Hohloser; Philippe Kolh; Jean-Yves Le Heuzey; Piotr Ponikowski; Frans H Rutten
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

7.  Effect of dronedarone on cardiovascular events in atrial fibrillation.

Authors:  Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly
Journal:  N Engl J Med       Date:  2009-02-12       Impact factor: 91.245
  7 in total
  3 in total

Review 1.  Blood coagulation factor XII--a neglected player in stroke pathophysiology.

Authors:  Mirko Pham; Guido Stoll; Bernhard Nieswandt; Martin Bendszus; Christoph Kleinschnitz
Journal:  J Mol Med (Berl)       Date:  2011-09-10       Impact factor: 4.599

2.  Completeness of prescription information in US commercial claims databases.

Authors:  Julie C Lauffenburger; Akhila Balasubramanian; Joel F Farley; Cathy W Critchlow; Cynthia D O'Malley; Mary T Roth; Virginia Pate; M Alan Brookhart
Journal:  Pharmacoepidemiol Drug Saf       Date:  2013-05-21       Impact factor: 2.890

3.  Analysis of QRS-T subtraction in unipolar atrial fibrillation electrograms.

Authors:  J L Salinet; J P V Madeiro; P C Cortez; P J Stafford; G André Ng; G André Ng; F S Schlindwein
Journal:  Med Biol Eng Comput       Date:  2013-04-07       Impact factor: 2.602
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.